Effect of the patient information brochure in communicating the risks associated with crizotinib treatment to patients with non‐small cell lung cancer (NSCLC) in Europe

Effect of the patient information brochure in communicating the risks associated with crizotinib treatment to patients with non‐small cell lung cancer (NSCLC) in Europe

Abstract Crizotinib (XALKORI®) is indicated for anaplastic lymphoma kinase‐positive and ROS1‐positive advanced non‐small cell lung cancer. This study evaluated the distribution of the crizotinib patient information brochure (PIB) in Europe and patient knowledge of the key messages in the PIB. A cros...

Full description

Bibliographic Details
Main Authors: Kui Huang, Terri Madison, Beatrice Wehler, Marcello Tiseo, Keith D. Wilner, Jingping Mo
Format: Article
Language:English
Published: Wiley 2020-04-01
Series:Pharmacology Research & Perspectives
Subjects:
crizotinib
patient information brochure
risk minimization
survey
Online Access:https://doi.org/10.1002/prp2.570

Internet

https://doi.org/10.1002/prp2.570

Similar Items